3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
20
Radiotherapy
16
Paclitaxel
14
Carboplatin
12
pembrolizumab
11
Drug Therapy
11
tislelizumab
10
Fluorouracil
8
Neoadjuvant Therapy
7
130-nm albumin-bound paclitaxel
7
sintilimab
5
Esophagectomy
5
toripalimab
4
Tegafur
4
TP protocol
4
Nivolumab
4
Irinotecan
4
Immunotherapy
4
spartalizumab
3
S 1 (combination)
3
Oxaliplatin
3
Leucovorin
3
Itraconazole
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
nimotuzumab
2
apatinib
2
Taxes
2
Radiotherapy, Intensity-Modulated
2
Immune Checkpoint Inhibitors
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Squamous Cell Carcinoma
×
Histamine H2 Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled